<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta http-equiv="X-UA-Compatible" content="ie=edge">
    <title>HTML Searcher</title>
    <link rel="stylesheet" href="https://stackpath.bootstrapcdn.com/bootstrap/4.3.1/css/bootstrap.min.css" integrity="sha384-ggOyR0iXCbMQv3Xipma34MD+dH/1fQ784/j6cY/iJTQUOhcWr7x9JvoRxT2MZw1T" crossorigin="anonymous">
    <style type="text/css">
    mark {
        background-color: gold;
    }
    </style>
    <script src="../text-marker.min.js"></script>
</head>
<body>

    <div class="container-fluid">        
        <h1 class="display-1 text-center">Text search <small>Example</small> </h1>
        <hr>
        
        <div class="row">
            <div class="col-sm-6">
                <form class="form-inline">
                    <label class="sr-only" for="initialText">Start</label>
                    <input type="text" class="form-control mb-2 mr-sm-2" id="initialText" placeholder="Stating text" />
                    <label class="sr-only" for="finalText">End</label>
                    <input type="text" class="form-control mb-2 mr-sm-2" id="finalText" placeholder="Ending text" />

                    <button id="searchBtn" type="button" class="btn btn-primary mb-2">Search</button>
                    <button id="cleanBtn" type="button" class="btn btn-danger mb-2">Clean</button>
                </form>
            </div>
            <div class="col-sm-6">

                <!-- HTML:Start -->
                <div id="article1-body" class="body">
                    <div class="section"><a name="d1e355">
                            <!-- named anchor --></a><p class="titulo_nivel_um"><font size="3" face="Verdana, Arial, Helvetica, sans-serif"><b>INTRODUCTION</b></font></p>
                        <p><font id="d1e358" size="2" face="Verdana, Arial, Helvetica, sans-serif">Atrial fibrillation (AF) is the most common arrhythmia occurring after coronary
                                                artery bypass graft (CABG) surgery and it is seen in approximately 15%-60% of
                                these
                                                patients. Postoperative AF (POAF) is associated with increased morbidity, mortality,
                                                and longer hospital stay; it is also associated with a two-to-three-fold increase
                                in
                                                postoperative stroke. Ageing, obesity, hypertension (HT), prior AF, and heart
                                                failure (HF) are found strongly associated with higher risk of POAF<sup>[</sup><sup>1</sup><sup>]</sup>.</font></p>
                        <p><font id="d1e367" size="2" face="Verdana, Arial, Helvetica, sans-serif">Vitamin D (vitD) has various cardiovascular pleiotropic effects by activating its
                                                nuclear receptor in cardiomyocytes and vascular endothelial cells and by regulating
                                                the renin-angiotensin-aldosterone system (RAAS), adiposity, and energy expenditure.
                                                There is inconsistent data about the association between vitD and POAF. POAF
                                                incidence was significantly higher in patients with vitD deficiency or insufficiency
                                                than in patients with normal vitD level in previous studies<sup>[</sup><sup>2</sup><sup>-</sup><sup>6</sup><sup>]</sup>. In our previous study, although there was a significant
                                                negative correlation between vitD and left atrial diameter, the vitD level was
                                not
                                                an independent predictor of POAF<sup>[</sup><sup>7</sup><sup>]</sup>.</font></p>
                        <p><font id="d1e387" size="2" face="Verdana, Arial, Helvetica, sans-serif">To the best of our knowledge, the relationship between preoperative vitD
                                                supplementation in patients with vitD deficiency/insufficiency and POAF has not
                                been
                                                studied before. Therefore, we assessed the preventive effect of vitD supplementation
                                                on POAF in patients who underwent CABG surgery with vitD
                                                deficiency/insufficiency.</font></p>
                    </div>
                    <div class="section"><a name="d1e389">
                            <!-- named anchor --></a><p class="titulo_nivel_um"><font size="3" face="Verdana, Arial, Helvetica, sans-serif"><b>METHODS</b></font></p>
                        <p><font id="d1e392" size="2" face="Verdana, Arial, Helvetica, sans-serif">Our study was a randomised, blinded clinical trial. The study group consisted of 328
                                                consecutive patients who underwent on-pump CABG surgery. Prevalence of vitD
                                                insufficiency and deficiency found were 24.3% (n=80) and 17% (n=56) among the
                                study
                                                population, respectively. Patients were assigned to receive either oral vitD (50.000
                                                IU) (treatment group; n=40 insufficiency patients, n=28 deficiency patients) or
                                not
                                                48 hours before CABG surgery. Patients were followed up during hospitalisation
                                                process with respect to new-onset AF. All investigators were blinded to treatment
                                                assignment. VitD supplementation was initiated in control group while discharging.
                                                The patients' data were analysed for AF in the postoperative period until discharge.
                                                The study was approved by the local ethics committee.</font></p>
                        <div class="section"><a name="d1e394">
                                <!-- named anchor --></a><p class="titulo_nivel_dois"><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Definition of POAF</b></font></p>
                            <p><font id="d1e397" size="2" face="Verdana, Arial, Helvetica, sans-serif">The study's main outcome was the occurrence of POAF from surgery until hospital
                                                    discharge. Continuous electrocardiogram (ECG) monitoring was performed up to
                                48
                                                    hours after the operation to detect new-onset AF. Subsequently, telemetric ECG
                                                    device was placed on the patients until the fifth postoperative day. The
                                                    presence of ECG-documented AF for at least 5 min was recorded and analysed as
                                                    POAF without symptoms. All symptomatic episodes detected by the patients or
                                                    clinical residents were confirmed by a 12-lead ECG, and at least 1 min was
                                                    recorded and analysed as POAF. Patients who developed AF in the postoperative
                                                    period until discharge were included in the POAF group.</font></p>
                            <p><font id="d1e399" size="2" face="Verdana, Arial, Helvetica, sans-serif">Patients who developed POAF were treated with intravenous beta-blocker as a
                                                    first-line rate control therapy. Intravenous amiodarone was initiated as a
                                                    first-line rhythm control therapy. If the heart rate was not tolerated despite
                                                    medical therapy (amiodarone, beta-blocker), electrical cardioversion was
                                                    performed if POAF had been occurred for &lt;48 hours. If POAF had been occurred
                                                    for ≥48 hours, left atrial clot was ruled out with transesophageal
                                                    echocardiography before electrical cardioversion. Anticoagulation therapy was
                                                    initiated in patients with POAF and continued for at least three months. The
                                                    decision to continue oral anticoagulation after three months was made according
                                                    to the CHA2DS2-VASC score [congestive HF, HT, age ≥75 years (2 points),
                                                    diabetes mellitus (DM), previous stroke/transient ischemic attack (TIA) (2
                                                    points), vascular disease, age 65-74 years, and gender (female)].</font></p>
                            <p><font id="d1e401" size="2" face="Verdana, Arial, Helvetica, sans-serif">Patient's data including age, gender, history of HT, hyperlipidemia (HL), chronic
                                                    kidney disease, DM, HF, chronic obstructive pulmonary disease (COPD), congenital
                                                    heart disease, valvular heart disease, liver disease, stroke, thyroid disease,
                                                    preoperative drug use [beta-blockers, diuretics, aspirin, angiotensin-converting
                                                    enzyme inhibitor/angiotensin receptor blockers (ACE-i/ARB), and statins],
                                                    echocardiographic variables such as ejection fraction (EF) and left atrial
                                                    diameter, and presence of valvular disease were retrieved from the medical
                                                    charts and included in the analysis.</font></p>
                        </div>
                        <div class="section"><a name="d1e403">
                                <!-- named anchor --></a><p class="titulo_nivel_dois"><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Echocardiographic Examination</b></font></p>
                            <p><font id="d1e406" size="2" face="Verdana, Arial, Helvetica, sans-serif">All patients underwent transthoracic echocardiography using Vivid S5 (GE
                                                    healthcare) echocardiography device and Mass S5 probe (2-4 MHz). Standard
                                                    two-dimensional and colour flow Doppler evaluation were acquired according to
                                                    the American Society of Echocardiography and European Society of
                                                    Echocardiography guidelines<sup>[</sup><sup>8</sup><sup>]</sup>. EF was measured according to the Simpson's method.
                                                    Left atrial diameter was measured in parasternal long axis view using
                                                    two-dimensional echocardiography at the left ventricular end-systole.</font></p>
                            <p><font id="d1e415" size="2" face="Verdana, Arial, Helvetica, sans-serif">The study's exclusion criteria were: patients with paroxysmal or persistent AF,
                                                    being on antiarrhythmic medications, patients who underwent pharmacological or
                                                    electrical cardioversion before CABG surgery due to reasons other than AF, and
                                                    patients who underwent other cardiac procedures in addition to CABG or who
                                                    planned to undergo emergency surgery. Furthermore, patients without vitD
                                                    insufficiency or deficiency were also excluded from the study.</font></p>
                        </div>
                        <div class="section"><a name="d1e417">
                                <!-- named anchor --></a><p class="titulo_nivel_dois"><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Laboratory Tests</b></font></p>
                            <p><font id="d1e420" size="2" face="Verdana, Arial, Helvetica, sans-serif">25-hydroxy (OH) vitD, calcium, and other biochemical and hematologic parameter
                                                    levels were measured following a fasting period of 8 hours. Serum 25-(OH) vitD
                                                    levels were measured by chemiluminescent immunoassay using a LIAISON analyser
                                                    (DiaSorin Inc). VitD deficiency was defined as serum levels of 25-(OH) vitD
                                                    &lt;20 ng/ml. VitD insufficiency was defined as a level of 20-29 ng/ml. Plasma
                                                    levels of 25-(OH) vitD &gt;30 ng/ml were defined as normal. Oral vitD
                                                    supplementation (50.000 U) was initiated 48 hours before CABG surgery.</font></p>
                        </div>
                        <div class="section"><a name="d1e422">
                                <!-- named anchor --></a><p class="titulo_nivel_dois"><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Statistical Analysis</b></font></p>
                            <p><font id="d1e425" size="2" face="Verdana, Arial, Helvetica, sans-serif">Statistical analysis was performed using the SPSS (version 20.0, SPSS Inc.,
                                                    Chicago, IL, USA) software package. Continuous variables were expressed as mean
                                                    ± standard deviation (mean± SD) and categorical variables were
                                                    expressed as a percentage (%). The Kolmogorov-Smirnov test was used to evaluate
                                                    variables distribution. Student's t-test was used to evaluate continuous
                                                    variables showing normal distribution and Mann-Whitney U-test was used to
                                                    evaluate variables that did not show normal distribution. A
                                                    <i>P</i>-value &lt;0.05 was considered statistically significant.</font></p>
                        </div>
                    </div>
                    <div class="section"><a name="d1e430">
                            <!-- named anchor --></a><p class="titulo_nivel_um"><font size="3" face="Verdana, Arial, Helvetica, sans-serif"><b>RESULTS</b></font></p>
                        <p><font id="d1e433" size="2" face="Verdana, Arial, Helvetica, sans-serif">The present study included 328 consecutive patients, of which 80 (24.3%) patients
                                had
                                                vitD insufficiency and 56 (17%) had vitD deficiency. <a href="#t1" name="idt1" class="caixa_link">Table 1</a> presents the main characteristics of the patients with and
                                                without vitD supplementation. There was no significant difference between these
                                two
                                                groups with regards to age (63.8±9.3 years <i>vs.</i>
                                                62.7±8.9 years, <i>P</i>=0.761), female gender (46.3%
                                                    <i>vs.</i> 48.1%, <i>P</i>=0.827), HT (62.5%
                                                    <i>vs.</i> 63.7%, <i>P</i>=0.834), DM (37.9%
                                                    <i>vs.</i> 35.4%, <i>P</i>=0.637), HL (32.8%
                                                    <i>vs.</i> 34.7%, <i>P</i>=0.682), smoking history (24.6%
                                                    <i>vs.</i> 27.1%, <i>P</i>=0.753), COPD (28.7%
                                                    <i>vs.</i> 26.9%, <i>P</i>=0.756), left atrial diameter
                                                (38.9 mm <i>vs.</i> 39.3 mm, <i>P</i>=0.837), left ventricular
                                                EF (62.7±6.9% <i>vs.</i> 61.3±7.1%,
                                                <i>P</i>=0.843), and duration of hospitalization (8.1±2.3 days
                                                    <i>vs.</i> 7.9±2.1 days, <i>P</i>=0.891) (<a href="#t1" name="idt1" class="caixa_link">Table 1</a>).</font></p>
                        <div class="tabela" id="t1">
                            <div class="table-wrap panel" style="display: float; clear: both; font-size: small;
                            font-family: Verdana, Arial, Helvetica, sans-serif;"><span class="caption">
                                <div class="titulo_alternativo" style="font-size: small; font-family: Verdana, Arial, Helvetica, sans-serif;"><strong>Table&nbsp;1 - </strong>Patient's characteristics.
                                </div></span><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" frame="hsides" rules="all">
                                <colgroup span="1">
                                    <col width="40%" span="1">
                                    <col width="20%" span="1">
                                    <col width="20%" span="1">
                                    <col width="20%" span="1">
                                </colgroup>
                                <thead>
                                    <tr>
                                        <th rowspan="2" colspan="1" align="left">Patient's characteristics</th>
                                        <th colspan="2" rowspan="1" align="center">Vitamin D supplementation</th>
                                        <th rowspan="2" colspan="1" align="center"><i>P</i></th>
                                    </tr>
                                    <tr>
                                        <th rowspan="1" colspan="1" align="center">(+)<br class="br">(n=68)
                                        </th>
                                        <th rowspan="1" colspan="1" align="center">(-)<br class="br">(n=68)
                                        </th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td rowspan="1" colspan="1" align="left">Age (years)</td>
                                        <td rowspan="1" colspan="1" align="center">63.8±9.3</td>
                                        <td rowspan="1" colspan="1" align="center">62.7±8.9</td>
                                        <td rowspan="1" colspan="1" align="center">0.761</td>
                                    </tr>
                                    <tr>
                                        <td rowspan="1" colspan="1" align="left">Female gender (%)</td>
                                        <td rowspan="1" colspan="1" align="center">46.3</td>
                                        <td rowspan="1" colspan="1" align="center">48.1</td>
                                        <td rowspan="1" colspan="1" align="center">0.827</td>
                                    </tr>
                                    <tr>
                                        <td rowspan="1" colspan="1" align="left">Hypertension (%)</td>
                                        <td rowspan="1" colspan="1" align="center">62.5</td>
                                        <td rowspan="1" colspan="1" align="center">63.7</td>
                                        <td rowspan="1" colspan="1" align="center">0.834</td>
                                    </tr>
                                    <tr>
                                        <td rowspan="1" colspan="1" align="left">Diabetes mellitus (%)</td>
                                        <td rowspan="1" colspan="1" align="center">37.9</td>
                                        <td rowspan="1" colspan="1" align="center">35.4</td>
                                        <td rowspan="1" colspan="1" align="center">0.637</td>
                                    </tr>
                                    <tr>
                                        <td rowspan="1" colspan="1" align="left">Hyperlipidemia (%)</td>
                                        <td rowspan="1" colspan="1" align="center">32.8</td>
                                        <td rowspan="1" colspan="1" align="center">34.7</td>
                                        <td rowspan="1" colspan="1" align="center">0.682</td>
                                    </tr>
                                    <tr>
                                        <td rowspan="1" colspan="1" align="left">Smoking history (%)</td>
                                        <td rowspan="1" colspan="1" align="center">24.6</td>
                                        <td rowspan="1" colspan="1" align="center">27.1</td>
                                        <td rowspan="1" colspan="1" align="center">0.753</td>
                                    </tr>
                                    <tr>
                                        <td rowspan="1" colspan="1" align="left">COPD, n (%)</td>
                                        <td rowspan="1" colspan="1" align="center">28.7</td>
                                        <td rowspan="1" colspan="1" align="center">26.9</td>
                                        <td rowspan="1" colspan="1" align="center">0.756</td>
                                    </tr>
                                    <tr>
                                        <td rowspan="1" colspan="1" align="left">Duration of hospitalization (days)</td>
                                        <td rowspan="1" colspan="1" align="center">8.1±2.3</td>
                                        <td rowspan="1" colspan="1" align="center">7.9±2.1</td>
                                        <td rowspan="1" colspan="1" align="center">0.891</td>
                                    </tr>
                                    <tr>
                                        <td rowspan="1" colspan="1" align="left">Left ventricular ejection fraction (%)</td>
                                        <td rowspan="1" colspan="1" align="center">62.7±6.9</td>
                                        <td rowspan="1" colspan="1" align="center">61.3±7.1</td>
                                        <td rowspan="1" colspan="1" align="center">0.843</td>
                                    </tr>
                                    <tr>
                                        <td rowspan="1" colspan="1" align="left">Left atrial diameter (mm)</td>
                                        <td rowspan="1" colspan="1" align="center">38.9</td>
                                        <td rowspan="1" colspan="1" align="center">39.3</td>
                                        <td rowspan="1" colspan="1" align="center">0.837</td>
                                    </tr>
                                    <tr>
                                        <td rowspan="1" colspan="1" align="left">Cross-clamp time (min)</td>
                                        <td rowspan="1" colspan="1" align="center">74 (71.0-78.0)</td>
                                        <td rowspan="1" colspan="1" align="center">75 (72-80)</td>
                                        <td rowspan="1" colspan="1" align="center">0.672</td>
                                    </tr>
                                    <tr>
                                        <td rowspan="1" colspan="1" align="left">Cardiopulmonary bypass time (min)</td>
                                        <td rowspan="1" colspan="1" align="center">96 (84.0-101)</td>
                                        <td rowspan="1" colspan="1" align="center">94 (80.0-98.0)</td>
                                        <td rowspan="1" colspan="1" align="center">0.718</td>
                                    </tr>
                                    <tr>
                                        <td rowspan="1" colspan="1" align="left">Beta-blocker therapy (%)</td>
                                        <td rowspan="1" colspan="1" align="center">86</td>
                                        <td rowspan="1" colspan="1" align="center">89</td>
                                        <td rowspan="1" colspan="1" align="center">0.584</td>
                                    </tr>
                                    <tr>
                                        <td rowspan="1" colspan="1" align="left">Statin therapy (%)</td>
                                        <td rowspan="1" colspan="1" align="center">92</td>
                                        <td rowspan="1" colspan="1" align="center">94</td>
                                        <td rowspan="1" colspan="1" align="center">0.783</td>
                                    </tr>
                                    <tr>
                                        <td rowspan="1" colspan="1" align="left">ACE-ı/ARB therapy (%)</td>
                                        <td rowspan="1" colspan="1" align="center">72</td>
                                        <td rowspan="1" colspan="1" align="center">70</td>
                                        <td rowspan="1" colspan="1" align="center">0.867</td>
                                    </tr>
                                    <tr>
                                        <td rowspan="1" colspan="1" align="left">Aspirin therapy (%)</td>
                                        <td rowspan="1" colspan="1" align="center">96</td>
                                        <td rowspan="1" colspan="1" align="center">93</td>
                                        <td rowspan="1" colspan="1" align="center">0.567</td>
                                    </tr>
                                    <tr>
                                        <td rowspan="1" colspan="1" align="left">Diuretics therapy (%)</td>
                                        <td rowspan="1" colspan="1" align="center">23</td>
                                        <td rowspan="1" colspan="1" align="center">21</td>
                                        <td rowspan="1" colspan="1" align="center">0.738</td>
                                    </tr>
                                </tbody>
                                </table>
                                <div class="table-wrap-foot">
                                <div class="footnote-table">
                                    <p><a name="d1e691">
                                            <!-- named anchor --></a>ACE-ı/ARB=angiotensin-converting enzyme inhibitor/angiotensin
                                                                    receptor blocker; COPD=chronic obstructive pulmonary disease
                                    </p>
                                </div>
                                </div>
                            </div>
                        </div>
                        <div class="caixa_imagem_legenda">
                            <div class="caixa_imagem"><a href="#t1" class="caixa_link" title="Table 1"><img src="http://static.bjcvs.org/images/imagensRBCCV/min/tabela-v33n4a347-t1.jpg"></a></div>
                            <div class="caixa_legenda"><span class="caption">
                                <div class="titulo_alternativo" style="font-size: small; font-family: Verdana, Arial, Helvetica, sans-serif;"><strong>Table&nbsp;1 - </strong>Patient's characteristics.
                                </div></span></div>
                        </div>
                        <p><font id="d1e693" size="2" face="Verdana, Arial, Helvetica, sans-serif">Also, there was no significant difference between these two groups with regards to
                                                medications, such as beta-blockers (86% <i>vs.</i> 89%,
                                                <i>P</i>=0.584), statin (92% <i>vs.</i> 94%,
                                                <i>P</i>=0.783), ACE-ı/ARB (72% <i>vs.</i> 70%,
                                                    <i>P</i>=0.867), aspirin (96% <i>vs.</i> 93%,
                                                    <i>P</i>=0.567), and diuretics (23% <i>vs.</i>. 21%,
                                                    <i>P</i>=0.738) (<a href="#t1" name="idt1" class="caixa_link">Table 1</a>). And
                                                there was no significant difference between them with regards to cross-clamp time
                                                (74 min <i>vs.</i> 75 min, <i>P</i>=0.672) and cardiopulmonary
                                                bypass time (96 min <i>vs.</i> 94 min, <i>P</i>=0718) (<a href="#t1" name="idt1" class="caixa_link">Table 1</a>).</font></p>
                        <p><font id="d1e745" size="2" face="Verdana, Arial, Helvetica, sans-serif">In addition, there was no significant difference between these two groups with
                                                regards to biochemical and haematological parameters, such as hemoglobin
                                                (14.1±2.3 <i>vs.</i> 14.6±2.8 g/dl,
                                                <i>P</i>=0.652), platelet (293.5±46.9 <i>vs.</i>
                                                289.3±49.6 10<sup>3</sup>/µL, <i>P</i>=0.563), white blood
                                                cell (7.9±3.7 <i>vs.</i> 8.2±3.4 10<sup>3</sup>/µL,
                                                    <i>P</i>=0.857), creatinine (1.03±0.29 <i>vs.</i>
                                                1.01±0.23 mg/dl, <i>P</i>=0.761), fasting plasma glucose
                                                (112.3±32.9 <i>vs.</i> 109.2±30.7 mg/dl, P=0.627),
                                                C-reactive protein (1.14±0.92 <i>vs.</i> 1.22±0.91 mg/dl,
                                                    <i>P</i>=0.738), total cholesterol (186.3±43.1
                                                    <i>vs.</i> 181.3±44.9 mg/dl, <i>P</i>=0.613),
                                                high-density lipoprotein (37.1±9.7 <i>vs.</i> 39.3±11.5
                                                mg/dl, <i>P</i>=0.514), low-density lipoprotein (163.4±43.8 vs
                                                165.9±45.7 mg/dl, <i>P</i>=0.628), and triglyceride
                                                (183.1±56.7 <i>vs.</i> 178.1±54.7 mg/dl
                                                <i>P</i>=0.485) (<a href="#t2" name="idt2" class="caixa_link">Table 2</a>).</font></p>
                        <div class="tabela" id="t2">
                            <div class="table-wrap panel" style="display: float; clear: both; font-size: small;
                            font-family: Verdana, Arial, Helvetica, sans-serif;"><span class="caption">
                                <div class="titulo_alternativo" style="font-size: small; font-family: Verdana, Arial, Helvetica, sans-serif;"><strong>Table&nbsp;2 - </strong>Laboratory parameters.
                                </div></span><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" frame="hsides" rules="all">
                                <colgroup span="1">
                                    <col width="40%" span="1">
                                    <col width="20%" span="1">
                                    <col width="20%" span="1">
                                    <col width="20%" span="1">
                                </colgroup>
                                <thead>
                                    <tr>
                                        <th rowspan="2" colspan="1" align="left">Laboratory parameters</th>
                                        <th colspan="2" rowspan="1" align="center">Vitamin D supplementation</th>
                                        <th rowspan="2" colspan="1" align="center"><i>P</i></th>
                                    </tr>
                                    <tr>
                                        <th rowspan="1" colspan="1" align="center">(+)<br class="br">(n=68)
                                        </th>
                                        <th rowspan="1" colspan="1" align="center">(-)<br class="br">(n=68)
                                        </th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td rowspan="1" colspan="1" align="left">Hemoglobin (g/dl)</td>
                                        <td rowspan="1" colspan="1" align="center">14.1±2.3 (14.7)</td>
                                        <td rowspan="1" colspan="1" align="center">14.6±2.8 (14.9)</td>
                                        <td rowspan="1" colspan="1" align="center">0.652</td>
                                    </tr>
                                    <tr>
                                        <td rowspan="1" colspan="1" align="left">Platelet (10<sup>3</sup>/µL)
                                        </td>
                                        <td rowspan="1" colspan="1" align="center">293.5±46.9 (302.8)</td>
                                        <td rowspan="1" colspan="1" align="center">289.3±49.6 298.3)</td>
                                        <td rowspan="1" colspan="1" align="center">0.563</td>
                                    </tr>
                                    <tr>
                                        <td rowspan="1" colspan="1" align="left">White blood cell (10<sup>3</sup>/µL)
                                        </td>
                                        <td rowspan="1" colspan="1" align="center">7.9±3.7 (8.7)</td>
                                        <td rowspan="1" colspan="1" align="center">8.2±3.4 (8.9)</td>
                                        <td rowspan="1" colspan="1" align="center">0.857</td>
                                    </tr>
                                    <tr>
                                        <td rowspan="1" colspan="1" align="left">Creatinine (mg/dl)</td>
                                        <td rowspan="1" colspan="1" align="center">1.03±0.29 (1.12)</td>
                                        <td rowspan="1" colspan="1" align="center">1.01±0.23 (1.08)</td>
                                        <td rowspan="1" colspan="1" align="center">0.761</td>
                                    </tr>
                                    <tr>
                                        <td rowspan="1" colspan="1" align="left">Fasting plasma glucose (mg/dl)</td>
                                        <td rowspan="1" colspan="1" align="center">112.3±32.9 (104.6)</td>
                                        <td rowspan="1" colspan="1" align="center">109.2±30.7 (106.9)</td>
                                        <td rowspan="1" colspan="1" align="center">0.627</td>
                                    </tr>
                                    <tr>
                                        <td rowspan="1" colspan="1" align="left">C-reactive protein (mg/dl)</td>
                                        <td rowspan="1" colspan="1" align="center">1.14±0.92 (0.97)</td>
                                        <td rowspan="1" colspan="1" align="center">1.22±0.91 (0.99)</td>
                                        <td rowspan="1" colspan="1" align="center">0.738</td>
                                    </tr>
                                    <tr>
                                        <td rowspan="1" colspan="1" align="left">Total cholesterol (mg/dl)</td>
                                        <td rowspan="1" colspan="1" align="center">186.3±43.1 (195.1)</td>
                                        <td rowspan="1" colspan="1" align="center">181.3±44.9 (192.7)</td>
                                        <td rowspan="1" colspan="1" align="center">0.613</td>
                                    </tr>
                                    <tr>
                                        <td rowspan="1" colspan="1" align="left">High-density lipoprotein (mg/dl)</td>
                                        <td rowspan="1" colspan="1" align="center">37.1±9.7 (39.3)</td>
                                        <td rowspan="1" colspan="1" align="center">39.3±11.5 (41.4)</td>
                                        <td rowspan="1" colspan="1" align="center">0.514</td>
                                    </tr>
                                    <tr>
                                        <td rowspan="1" colspan="1" align="left">Low-density lipoprotein (mg/dl)</td>
                                        <td rowspan="1" colspan="1" align="center">163.4±43.8 (184.2)</td>
                                        <td rowspan="1" colspan="1" align="center">165.9±45.7 (182.7)</td>
                                        <td rowspan="1" colspan="1" align="center">0.628</td>
                                    </tr>
                                    <tr>
                                        <td rowspan="1" colspan="1" align="left">Triglyceride (mg/dl)</td>
                                        <td rowspan="1" colspan="1" align="center">183.1±56.7 (192.6)</td>
                                        <td rowspan="1" colspan="1" align="center">178.1±54.7 (189.4)</td>
                                        <td rowspan="1" colspan="1" align="center">0.485</td>
                                    </tr>
                                    <tr>
                                        <td rowspan="1" colspan="1" align="left">Vitamin D level (deficiency group) (ng/ml)</td>
                                        <td rowspan="1" colspan="1" align="center">11.4±4.9</td>
                                        <td rowspan="1" colspan="1" align="center">10.9±5.2</td>
                                        <td rowspan="1" colspan="1" align="center">0.681</td>
                                    </tr>
                                    <tr>
                                        <td rowspan="1" colspan="1" align="left">Vitamin D level (ınsufficiency group)
                                                                            (ng/ml)
                                        </td>
                                        <td rowspan="1" colspan="1" align="center">24.6±3.7</td>
                                        <td rowspan="1" colspan="1" align="center">24.9±3.9</td>
                                        <td rowspan="1" colspan="1" align="center">0.837</td>
                                    </tr>
                                </tbody>
                                </table>
                            </div>
                        </div>
                        <div class="caixa_imagem_legenda">
                            <div class="caixa_imagem"><a href="#t2" class="caixa_link" title="Table 2"><img src="http://static.bjcvs.org/images/imagensRBCCV/min/tabela-v33n4a347-t2.jpg"></a></div>
                            <div class="caixa_legenda"><span class="caption">
                                <div class="titulo_alternativo" style="font-size: small; font-family: Verdana, Arial, Helvetica, sans-serif;"><strong>Table&nbsp;2 - </strong>Laboratory parameters.
                                </div></span></div>
                        </div>
                        <p><font id="d1e959" size="2" face="Verdana, Arial, Helvetica, sans-serif">Regarding to mean vitD level of insufficiency (24.6±3.7 <i>vs.</i>
                                                24.9±3.9 ng/ml, <i>P</i>=0.837) and deficiency patients
                                                (11.4±4.9 <i>vs.</i> 10.9±5.2 ng/ml,
                                                <i>P</i>=0.681), there was no significant difference between treatment and
                                                control groups (<a href="#t2" name="idt2" class="caixa_link">Table 2</a>).</font></p>
                        <p><font id="d1e976" size="2" face="Verdana, Arial, Helvetica, sans-serif">Although the occurrence of POAF was not significantly different among treatment and
                                                control groups in patients with vitD insufficiency (31% <i>vs.</i> 33%,
                                                    <i>P</i>=0.538), there was a significant difference between these two
                                                groups with regards to POAF in patients with vitD deficiency (18%
                                                    <i>vs.</i> 29%, <i>P</i>=0.02) (<a href="#t3" name="idt3" class="caixa_link">Table 3</a>).</font></p>
                        <div class="tabela" id="t3">
                            <div class="table-wrap panel" style="display: float; clear: both; font-size: small;
                            font-family: Verdana, Arial, Helvetica, sans-serif;"><span class="caption">
                                <div class="titulo_alternativo" style="font-size: small; font-family: Verdana, Arial, Helvetica, sans-serif;"><strong>Table&nbsp;3 - </strong>Prevalence of postoperative atrial fibrillation (POAF).
                                </div></span><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" frame="hsides" rules="all">
                                <colgroup span="1">
                                    <col width="20%" span="1">
                                    <col width="20%" span="1">
                                    <col width="20%" span="1">
                                    <col width="20%" span="1">
                                    <col width="20%" span="1">
                                </colgroup>
                                <thead>
                                    <tr>
                                        <th colspan="2" rowspan="2" align="left">&nbsp;</th>
                                        <th colspan="2" rowspan="1" align="center">Vitamin D supplementation</th>
                                        <th rowspan="2" colspan="1" align="center"><i>P</i></th>
                                    </tr>
                                    <tr>
                                        <th rowspan="1" colspan="1" align="center">(+)<br class="br">(n=68)
                                        </th>
                                        <th rowspan="1" colspan="1" align="center">(-)<br class="br">(n=68)
                                        </th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td rowspan="2" colspan="1" align="center">POAF (%)</td>
                                        <td rowspan="1" colspan="1" align="center">Vitamin D insufficiency group, n (80)</td>
                                        <td rowspan="1" colspan="1" align="center">31</td>
                                        <td rowspan="1" colspan="1" align="center">33</td>
                                        <td rowspan="1" colspan="1" align="center">0.538</td>
                                    </tr>
                                    <tr>
                                        <td rowspan="1" colspan="1" align="center">Vitamin D deficiency group, n (56)</td>
                                        <td rowspan="1" colspan="1" align="center">18</td>
                                        <td rowspan="1" colspan="1" align="center">29</td>
                                        <td rowspan="1" colspan="1" align="center">0.02</td>
                                    </tr>
                                </tbody>
                                </table>
                            </div>
                        </div>
                        <div class="caixa_imagem_legenda">
                            <div class="caixa_imagem"><a href="#t3" class="caixa_link" title="Table 3"><img src="http://static.bjcvs.org/images/imagensRBCCV/min/tabela-v33n4a347-t3.jpg"></a></div>
                            <div class="caixa_legenda"><span class="caption">
                                <div class="titulo_alternativo" style="font-size: small; font-family: Verdana, Arial, Helvetica, sans-serif;"><strong>Table&nbsp;3 - </strong>Prevalence of postoperative atrial fibrillation (POAF).
                                </div></span></div>
                        </div>
                    </div>
                    <div class="section"><a name="d1e1045">
                            <!-- named anchor --></a><p class="titulo_nivel_um"><font size="3" face="Verdana, Arial, Helvetica, sans-serif"><b>DISCUSSION</b></font></p>
                        <p><font id="d1e1048" size="2" face="Verdana, Arial, Helvetica, sans-serif">This study demonstrated that preoperative vitD supplementation was significantly
                                                preventive to the occurrence of POAF in patients with vitD deficiency while it
                                was
                                                not preventive to the occurrence of POAF in those with vitD insufficiency.
                                                Beneficial effects of preoperative vitD supplementation might be associated with
                                                tend to more occurrence of POAF in patients with vitD deficiency.</font></p>
                        <p><font id="d1e1050" size="2" face="Verdana, Arial, Helvetica, sans-serif">AF is the most common sustained arrhythmia and it has a major impact on the morbidity
                                                and mortality of general population. The risk of AF increases up to 26% after
                                the
                                                age of 40. It is estimated that AF may account for 10% to 15% of all strokes,
                                with
                                                an associated mortality of up to 1.9-fold<sup>[</sup><sup>9</sup><sup>]</sup>. In previous studies, ageing, male gender, COPD, HF, DM,
                                                preoperative AF attacks, chronic renal disease, metabolic syndrome, increased
                                                cross-clamp times, increased inflammatory markers, and left atrial diameter were
                                                found to be independent variables predicting the development of
                                                    POAF<sup>[</sup><sup>10</sup><sup>]</sup>.</font></p>
                        <p><font id="d1e1066" size="2" face="Verdana, Arial, Helvetica, sans-serif">Several potential mechanisms have described the association between vitD and
                                                    AF<sup>[</sup><sup>11</sup><sup>]</sup>. VitD
                                                insufficiency was associated with endothelial dysfunction and subclinical
                                                    atherosclerosis<sup>[</sup><sup>12</sup><sup>]</sup>. VitD regulates inflammatory responses and up-regulates the
                                                expression of anti-inflammatory cytokines, such as interleukin 10 (IL-10) and
                                IL-6,
                                                according to in-vitro experiments<sup>[</sup><sup>13</sup><sup>]</sup>. Also, vitD regulates RAAS activity. Activated RAAS can
                                                lead to an increase in new-onset AF<sup>[</sup><sup>14</sup><sup>]</sup>. It is postulated that tissue RAAS can induce apoptosis
                                                of cardiomyocytes and can contribute to changes in atrial structure<sup>[</sup><sup>15</sup><sup>]</sup>.</font></p>
                        <p><font id="d1e1104" size="2" face="Verdana, Arial, Helvetica, sans-serif">There were inconsistent results regarding low vitD levels and AF. Demir et
                                                    al.<sup>[</sup><sup>16</sup><sup>]</sup> reported a
                                                strong relationship between vitD deficiency and non-valvular AF. Serum vitD level
                                                was significantly associated with AF in Chinese patients with persistent nonvalvular
                                                    AF<sup>[</sup><sup>17</sup><sup>]</sup>. Hanafy et
                                                    al.<sup>[</sup><sup>18</sup><sup>]</sup> revealed
                                                the direct electromechanical effects on the left atrium after vitD administration
                                                and found that it could effectively prevent and terminate AF.</font></p>
                        <p><font id="d1e1128" size="2" face="Verdana, Arial, Helvetica, sans-serif">On the other hand, Rienstra et al.<sup>[</sup><sup>19</sup><sup>]</sup> reported that vitD deficiency does not promote the
                                                development of AF. Additionally, Qayyum et al.<sup>[20]</sup> also showed that there
                                                was no significant association between vitD deficiency and AF. Another prospective
                                                cohort study did not support the hypothesis that vitD level is associated with
                                                    AF<sup>[21]</sup>.</font></p>
                        <p><font id="d1e1143" size="2" face="Verdana, Arial, Helvetica, sans-serif">In the same manner, there were inconsistent results regarding preoperative serum vitD
                                                level and POAF. POAF incidence was significantly higher in patients with vitD
                                                deficiency or insufficiency than in patients with normal vitD level in previous
                                                    studies<sup>[</sup><sup>2</sup><sup>,</sup><sup>3</sup><sup>]</sup>. In our previous study, although
                                                there was a significant negative correlation between vitD and left atrial diameter,
                                                vitD level was not an independent predictor for POAF<sup>[</sup><sup>7</sup><sup>]</sup>.</font></p>
                        <p><font id="d1e1163" size="2" face="Verdana, Arial, Helvetica, sans-serif">Several studies demonstrated that platelets play a critical and precipitating role
                                in
                                                AF occurrence as the volume and distribution width of platelets and the factors
                                of
                                                platelet activity appeared to be significantly higher in AF patients than in sinus
                                                rhythm patients. Haematological indices red blood cell distribution width (RDW)
                                and
                                                mean platelet volume (MPV) are currently recognised as risk factors for POAF.
                                MPV,
                                                as a valuable haematological parameter in complete blood count test, could strongly
                                                predict the occurrence of paroxysmal, persistent, or permanent AF<sup>[</sup><sup>22</sup><sup>-</sup><sup>25</sup><sup>]</sup>. Our study did not include aforementioned haematological
                                                parameters such as MPV and RDW. In our study, there was no significant association
                                                between platelet count and POAF.</font></p>
                        <p><font id="d1e1176" size="2" face="Verdana, Arial, Helvetica, sans-serif">There are scarce data regarding the preventive role of preoperative vitD
                                                supplementation on POAF in patients with vitD insufficiency and deficiency.
                                                Therefore, we aimed to evaluate the preventive role of vitD supplementation. This
                                                study revealed that preoperative vitD supplementation was significantly preventive
                                                to the occurrence of POAF in patients with vitD deficiency while it was not
                                                preventive to the occurrence of POAF in those with vitD insufficiency. Preventive
                                                effect of vitD supplementation might be associated with direct electromechanical
                                                effects on the left atrium, regulating RAAS and inflammatory responses. Further
                                                randomised clinical studies with larger study population are needed in this
                                                field.</font></p>
                        <div class="section"><a name="d1e1178">
                                <!-- named anchor --></a><p class="titulo_nivel_dois"><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Limitations of the Study</b></font></p>
                            <p><font id="d1e1181" size="2" face="Verdana, Arial, Helvetica, sans-serif">Our study has some limitations: first, AF was diagnosed by ECG monitoring only
                                                    during hospitalisation process; second, this study has a small sample size;
                                                    third, vitD level was measured at a single point in time; fourth, the lack of
                                                    parathyroid hormone levels measurement; and fifth, the lack of haematological
                                                    markers such as MPV and RDW.</font></p>
                        </div>
                    </div>
                    <div class="section"><a name="d1e1183">
                            <!-- named anchor --></a><p class="titulo_nivel_um"><font size="3" face="Verdana, Arial, Helvetica, sans-serif"><b>CONCLUSION</b></font></p>
                        <p><font id="d1e1186" size="2" face="Verdana, Arial, Helvetica, sans-serif">To the best of our knowledge, this study is the first to evaluate the preventive
                                                effect of vitD on POAF in patients with vitD insufficiency and deficiency. In
                                this
                                                study, preoperative vitD supplementation was found to be significantly preventive
                                to
                                                the occurrence of POAF in patients with vitD deficiency while it was not found
                                to be
                                                preventive to the occurrence of POAF in those with vitD insufficiency. VitD
                                                deficiency should be considered in patients with POAF especially resistant to
                                                medical and electrical cardioversion. Further prospective and randomised studies
                                                with larger number of patients are required due to the relatively small number
                                of
                                                patients in the present study.</font></p>
                    </div>
                    </div>
                <!-- HTML:End -->

            </div>
        </div>

    </div>

    <script>
        var instance = new TextMarker('.body', { debug : false });
        
        var processMarker = function() {
            var startText = document.getElementById('initialText').value;
            var finalText = document.getElementById('finalText').value;  
                        
            instance.mark(startText, finalText);
        }

        //var marker1 = new Mark(document.querySelector('.body'));
        //console.log(marker1);
        
        // searchBtn
        document.getElementById('searchBtn').addEventListener('click', processMarker);
        
        document.getElementById('cleanBtn').addEventListener('click', function(){
            instance.unmark();
        });

        //console.log(internalSelector);
    </script>
    
</body>
</html>